Capsid-incorporation of antigens into adenovirus capsid proteins for a vaccine approach.
Capsid-incorporation of antigens into adenovirus capsid proteins for a vaccine approach.
复制标题
DOI：
10.1021/mp100214b
复制
发表时间：
2011-02-07
影响因子：
4.9
通讯作者：
Matthews QL
中科院分区：
文献类型：
--
作者：
Matthews QL
一些病毒载体是细胞和体液反应的有效诱导剂；因此，病毒载体可用于预防癌症或传染病的疫苗。本报告将重点关注腺病毒（Ad）载体。传统的病毒载体疫苗接种体现了载体利用宿主细胞机制表达抗原的概念，这些抗原在病毒载体内被编码为转基因。在动物模型系统中使用这种方法取得了一些临床前成功。然而，在某些情况下，这些传统的基于ad的疫苗产生了不理想的临床结果。这些次优结果部分归因于先前存在的血清5型Ad （Ad5）免疫。为了解决这个问题，“抗原衣壳结合”策略已经被开发出来，以避免与传统的Ad载体转基因表达抗原相关的缺点。这种策略体现了抗原肽在病毒载体衣壳结构内的结合。将免疫原性肽结合到Ad衣壳中提供了潜在的优势。重要的是，通过抗原衣壳结合方法接种疫苗可产生强烈的体液反应，类似于天然Ad衣壳蛋白产生的反应。这种策略也允许增强抗原特异性反应。这一策略可能是改进疫苗方案的前进方向，特别是对于那些需要强烈体液抗原反应的感染。
Some viral vectors are potent inducers of cellular and humoral responses; therefore, viral vectors can be used to vaccinate against cancer or infectious diseases. This report will focus on adenovirus (Ad)-based vectors. Traditional viral-vector vaccination embodies the concept that the vector uses the host-cell machinery to express antigens that are encoded as transgenes within the viral vector. Several preclinical successes have used this approach in animal model systems. However, in some instances, these conventional Ad-based vaccines have yielded suboptimal clinical results. These suboptimal results are ascribed, in part, to preexisting Ad serotype 5 (Ad5) immunity. To address this issue, the “antigen capsid-incorporation” strategy has been developed to circumvent the drawbacks associated with conventional transgene expression of antigens by Ad vectors. This strategy embodies the incorporation of antigenic peptides within the capsid structure of viral vectors. Incorporating immunogenic peptides into the Ad capsid offers potential advantages. Importantly, vaccination by means of the antigen capsid-incorporated approach results in a strong humoral response, similar to the response generated by native Ad capsid proteins. This strategy also allows for the boosting of antigenic specific responses. This strategy may be the way forward for improved vaccine schemes, especially for those infections requiring a strong humoral antigenic response.
登录
查看更多内容
影响因子：
5.4
作者：
Bayer, Wibke;Tenbusch, Matthias;Wildner, Oliver
通讯作者：
Wildner, Oliver
影响因子：
5.5
作者：
Bangari, DS;Mittal, SK
通讯作者：
Mittal, SK
影响因子：
5.4
作者：
Arnold, Gail Ferstandig;Velasco, Paola K.;Arnold, Eddy
通讯作者：
Arnold, Eddy
影响因子：
5.4
作者：
CrawfordMiksza, L;Schnurr, DP
通讯作者：
Schnurr, DP
影响因子：
11.4
作者：
Fabry, CMS;Rosa-Calatrava, M;Schoehn, G
通讯作者：
Schoehn, G